search for books and compare prices
Hellen Gelband has written 8 work(s)
Search for other authors with the same name
displaying 1 to 8 | at end
show results in order: alphabetically | oldest to newest | newest to oldest
Cover for 9781464803499 Cover for 9781464803505 Cover for 9780309103848 Cover for 9780309092180 Cover for 9780309087254 Cover for 9780309074025 Cover for 9780309075633 Cover for 9780309068888
cover image for 9781464803499
Product Description: Volume 3, Cancer, presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers. The DCP3 evaluation of cancer will indicate where cancer treatment is ineffective and wasteful, and offer alternative cancer care packages that are cost-effective and suited to low-resource settings...read more
By Hellen Gelband (editor), Susan Horton (editor), Prabhat Jha (editor) and Rengaswamy Sankaranarayanan (editor)

Paperback:

9781464803499, titled "Cancer: Cancer" | 3 edition (World Bank, November 9, 2015), cover price $35.00 | About this edition: Volume 3, Cancer, presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers.

cover image for 9781464803505
Product Description: Volume 2, Cancer, presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers. The DCP3 evaluation of cancer will indicate where cancer treatment is ineffective and wasteful, and offer alternative cancer care packages that are cost-effective and suited to low-resource settings...read more
By Hellen Gelband (editor), Susan Horton (editor), Prabhat Jha (editor) and Rengaswamy Sankaranarayanan (editor)

Hardcover:

9781464803505 | 3 edition (World Bank, November 25, 2015), cover price $55.00 | About this edition: Volume 2, Cancer, presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers.

cover image for 9780309103848
Product Description: Cancer is low or absent on the health agendas of low- and middle-income countries (LMCs) despite the fact that more people die from cancer in these countries than from AIDS and malaria combined. International health organizations, bilateral aid agencies, and major foundations—which are instrumental in setting health priorities—also have largely ignored cancer in these countries...read more
By Hellen Gelband (editor) and Frank A. Sloan (editor)

Paperback:

9780309103848 | 1 edition (Natl Academy Pr, January 31, 2007), cover price $49.00 | About this edition: Cancer is low or absent on the health agendas of low- and middle-income countries (LMCs) despite the fact that more people die from cancer in these countries than from AIDS and malaria combined.

cover image for 9780309092180
Product Description: For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections. Today, however, these drugs no longer work against the deadliest form of malaria that exists throughout the world...read more
By Kenneth J. Arrow (editor), Hellen Gelband (editor) and Claire B. Panosian (editor)

Hardcover:

9780309092180 | Natl Academy Pr, September 1, 2004, cover price $49.95 | About this edition: For more than 50 years, low-cost antimalarial drugs silently saved millions of lives and cured billions of debilitating infections.

cover image for 9780309087254
Product Description: National expenditures for medical care in the months and days preceding death are enormous. But we do not know whether that money is buying good quality care or optimizing the quality of life of those dying, or whether the situation is getting better or worse over time...read more (view table of contents, read Amazon.com's description)

Paperback:

9780309087254 | Natl Academy Pr, March 1, 2003, cover price $33.00 | About this edition: National expenditures for medical care in the months and days preceding death are enormous.

cover image for 9780309074025
Product Description: In our society’s aggressive pursuit of cures for cancer, we have neglected symptom control and comfort care. Less than one percent of the National Cancer Institute’s budget is spent on any aspect of palliative care research or education, despite the half million people who die of cancer each year and the larger number living with cancer and its symptoms...read more (view table of contents, read Amazon.com's description)
By Kathleen M. Foley (editor) and Hellen Gelband (editor)

Paperback:

9780309074025 | Natl Academy Pr, October 1, 2001, cover price $45.00 | About this edition: In our society’s aggressive pursuit of cures for cancer, we have neglected symptom control and comfort care.

cover image for 9780309075633
Product Description: It is innately human to comfort and provide care to those suffering from cancer, particularly those close to death. Yet what seems self-evident at an individual, personal level has, by and large, not guided policy at the level of institutions in this country...read more

Paperback:

9780309075633 | Natl Academy Pr, June 1, 2001, cover price $21.00 | About this edition: It is innately human to comfort and provide care to those suffering from cancer, particularly those close to death.

cover image for 9780309068888
Product Description: Increasingly over the past five years, uncertainty about reimbursement for routine patient care has been suspected as contributing to problems enrolling people in clinical trials. Clinical trial investigators cannot guarantee that Medicare will pay for the care required, and they must disclose this uncertainty to potential participants during the informed consent process...read more
By Henry J. Aaron (editor), Hellen Gelband (illustrator) and Institute of Medicine (other contributor)

Paperback:

9780309068888 | Natl Academy Pr, April 1, 2000, cover price $18.00 | About this edition: Increasingly over the past five years, uncertainty about reimbursement for routine patient care has been suspected as contributing to problems enrolling people in clinical trials.

displaying 1 to 8 | at end